IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Search
How mobile medical clinics tackle health equity Down Under
We support Heart of Australia to improve health in rural communities
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Lothar Halmer
Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
Therapeutics
Therapeutics
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
Boehringer Ingelheim and Vétérinaires sans Frontières Germany fight rabies in Kenya
Partnership aims to reduce rabies cases in Machakos County, with Boehringer Ingelheim providing vaccine doses and funding.
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
Meet the Partnering Team Video 2023
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
Explore our company
Make your next career step at Boehringer Ingelheim. Explore our various fields to find out more about employment opportunities in your area of interest.
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
World water day 2019
Boehringer Ingelheim started a social project in Mexico to preserve the aquifer and to ensure the water supply for dog shelters. Rainwater collector will save 180,000 liters of rainwater every year.
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Submit your animal health partnering opportunity
Information on how to submit your animal health innovation opportunity direct to Boehringer Ingelheim’s partnering team
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
Earthquakes Türkiye & Syria
Support for those impacted by Türkiye & Syria earthquakes
Thelaziosis dog eyeworms
Have you heard of Thelaziosis? In Europe, some fruit flies host an emerging parasite known as “eyeworm”, an infestation which causes more or less severe conjunctivitis, sometimes leading to corneal ulcers and even blindness in dogs.
TCO patient podcasts
From clinical trials to living with cancer, hear patient perspectives on different cancer topics in this podcast series.
History
History
Making sustainable medicines through eco-design
Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Rafał Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in our Global Business Service (GBS) Center in Wroclaw, looks back on a bustling beginning with Boehringer Ingelheim – for him and the Center alike.